Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

Elena Zamagni, Alessandro Petrucci, Patrizia Tosi, Paola Tacchetti, Giulia Perrone, Annamaria Brioli, Lucia Pantani, Beatrice Zannetti, Carolina Terragna, Michele Baccarani, Michele Cavo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thal-dex (TD) is an effective therapy for advanced MM. We evaluated TD as salvage treatment of MM patients at first relapse. Thal was given at a daily dose of 100 or 200 mg until progression. Dex was administered 160 mg/month. One hundred patients were enrolled. First line therapy included ASCT (72%) and conventional CHT (28%). Fifty-nine percent received a fixed thal dose of 100 mg/day. The most frequent adverse events were constipation (42%), peripheral neuropathy (58%, 5% grade 3), bradycardia (20%), skin rash (11%), and VTE (7%). Discontinuation of thal due to adverse events was recorded in eight patients. On ITT, 46% of patients achieved at least a PR. Median DOR was 28 months, median time to next therapy was 15.5 months. Median OS, TTP, and PFS were 43, 22, and 21 months, respectively. TTP and PFS were significantly longer for patients with at least PR to TD. TD was an effective salvage treatment for MM patients at first relapse, as demonstrated by durable disease control and prolonged OS. TD was well tolerated, as reflected by the long stay on treatment without disease progression (median 25 months) and a low discontinuation rate due to toxicity (8%).

Original languageEnglish
Pages (from-to)419-426
Number of pages8
JournalAnnals of Hematology
Volume91
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Thalidomide
Multiple Myeloma
Dexamethasone
Recurrence
Salvage Therapy
Therapeutics
Peripheral Nervous System Diseases
Constipation
Bradycardia
Exanthema
Disease Progression

Keywords

  • First relapse
  • Multiple myeloma
  • Overall survival
  • Peripheral neuropathy
  • Progression free survival
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Zamagni, E., Petrucci, A., Tosi, P., Tacchetti, P., Perrone, G., Brioli, A., ... Cavo, M. (2012). Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. Annals of Hematology, 91(3), 419-426. https://doi.org/10.1007/s00277-011-1320-2

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. / Zamagni, Elena; Petrucci, Alessandro; Tosi, Patrizia; Tacchetti, Paola; Perrone, Giulia; Brioli, Annamaria; Pantani, Lucia; Zannetti, Beatrice; Terragna, Carolina; Baccarani, Michele; Cavo, Michele.

In: Annals of Hematology, Vol. 91, No. 3, 03.2012, p. 419-426.

Research output: Contribution to journalArticle

Zamagni, E, Petrucci, A, Tosi, P, Tacchetti, P, Perrone, G, Brioli, A, Pantani, L, Zannetti, B, Terragna, C, Baccarani, M & Cavo, M 2012, 'Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma', Annals of Hematology, vol. 91, no. 3, pp. 419-426. https://doi.org/10.1007/s00277-011-1320-2
Zamagni, Elena ; Petrucci, Alessandro ; Tosi, Patrizia ; Tacchetti, Paola ; Perrone, Giulia ; Brioli, Annamaria ; Pantani, Lucia ; Zannetti, Beatrice ; Terragna, Carolina ; Baccarani, Michele ; Cavo, Michele. / Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. In: Annals of Hematology. 2012 ; Vol. 91, No. 3. pp. 419-426.
@article{dea75c04b4a9432fbf2899c47907ad2e,
title = "Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma",
abstract = "Thal-dex (TD) is an effective therapy for advanced MM. We evaluated TD as salvage treatment of MM patients at first relapse. Thal was given at a daily dose of 100 or 200 mg until progression. Dex was administered 160 mg/month. One hundred patients were enrolled. First line therapy included ASCT (72{\%}) and conventional CHT (28{\%}). Fifty-nine percent received a fixed thal dose of 100 mg/day. The most frequent adverse events were constipation (42{\%}), peripheral neuropathy (58{\%}, 5{\%} grade 3), bradycardia (20{\%}), skin rash (11{\%}), and VTE (7{\%}). Discontinuation of thal due to adverse events was recorded in eight patients. On ITT, 46{\%} of patients achieved at least a PR. Median DOR was 28 months, median time to next therapy was 15.5 months. Median OS, TTP, and PFS were 43, 22, and 21 months, respectively. TTP and PFS were significantly longer for patients with at least PR to TD. TD was an effective salvage treatment for MM patients at first relapse, as demonstrated by durable disease control and prolonged OS. TD was well tolerated, as reflected by the long stay on treatment without disease progression (median 25 months) and a low discontinuation rate due to toxicity (8{\%}).",
keywords = "First relapse, Multiple myeloma, Overall survival, Peripheral neuropathy, Progression free survival, Thalidomide",
author = "Elena Zamagni and Alessandro Petrucci and Patrizia Tosi and Paola Tacchetti and Giulia Perrone and Annamaria Brioli and Lucia Pantani and Beatrice Zannetti and Carolina Terragna and Michele Baccarani and Michele Cavo",
year = "2012",
month = "3",
doi = "10.1007/s00277-011-1320-2",
language = "English",
volume = "91",
pages = "419--426",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

AU - Zamagni, Elena

AU - Petrucci, Alessandro

AU - Tosi, Patrizia

AU - Tacchetti, Paola

AU - Perrone, Giulia

AU - Brioli, Annamaria

AU - Pantani, Lucia

AU - Zannetti, Beatrice

AU - Terragna, Carolina

AU - Baccarani, Michele

AU - Cavo, Michele

PY - 2012/3

Y1 - 2012/3

N2 - Thal-dex (TD) is an effective therapy for advanced MM. We evaluated TD as salvage treatment of MM patients at first relapse. Thal was given at a daily dose of 100 or 200 mg until progression. Dex was administered 160 mg/month. One hundred patients were enrolled. First line therapy included ASCT (72%) and conventional CHT (28%). Fifty-nine percent received a fixed thal dose of 100 mg/day. The most frequent adverse events were constipation (42%), peripheral neuropathy (58%, 5% grade 3), bradycardia (20%), skin rash (11%), and VTE (7%). Discontinuation of thal due to adverse events was recorded in eight patients. On ITT, 46% of patients achieved at least a PR. Median DOR was 28 months, median time to next therapy was 15.5 months. Median OS, TTP, and PFS were 43, 22, and 21 months, respectively. TTP and PFS were significantly longer for patients with at least PR to TD. TD was an effective salvage treatment for MM patients at first relapse, as demonstrated by durable disease control and prolonged OS. TD was well tolerated, as reflected by the long stay on treatment without disease progression (median 25 months) and a low discontinuation rate due to toxicity (8%).

AB - Thal-dex (TD) is an effective therapy for advanced MM. We evaluated TD as salvage treatment of MM patients at first relapse. Thal was given at a daily dose of 100 or 200 mg until progression. Dex was administered 160 mg/month. One hundred patients were enrolled. First line therapy included ASCT (72%) and conventional CHT (28%). Fifty-nine percent received a fixed thal dose of 100 mg/day. The most frequent adverse events were constipation (42%), peripheral neuropathy (58%, 5% grade 3), bradycardia (20%), skin rash (11%), and VTE (7%). Discontinuation of thal due to adverse events was recorded in eight patients. On ITT, 46% of patients achieved at least a PR. Median DOR was 28 months, median time to next therapy was 15.5 months. Median OS, TTP, and PFS were 43, 22, and 21 months, respectively. TTP and PFS were significantly longer for patients with at least PR to TD. TD was an effective salvage treatment for MM patients at first relapse, as demonstrated by durable disease control and prolonged OS. TD was well tolerated, as reflected by the long stay on treatment without disease progression (median 25 months) and a low discontinuation rate due to toxicity (8%).

KW - First relapse

KW - Multiple myeloma

KW - Overall survival

KW - Peripheral neuropathy

KW - Progression free survival

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84857362265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857362265&partnerID=8YFLogxK

U2 - 10.1007/s00277-011-1320-2

DO - 10.1007/s00277-011-1320-2

M3 - Article

VL - 91

SP - 419

EP - 426

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -